Literature DB >> 11700581

Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective.

A Ament1, D S Fedson, P Christie.   

Abstract

Most studies of the cost-effectiveness of pneumococcal vaccination show very favorable cost-effectiveness ratios for preventing pneumococcal pneumonia, but they make the controversial assumption that vaccination is equally effective in preventing bacteremic (BPP) and nonbacteremic (NBPP) pneumonia. However, the results of our study showed that, compared with preventing BPP alone, the cost-effectiveness of pneumococcal vaccination increased substantially even when only a small proportion of additional cases of NBPP were prevented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11700581     DOI: 10.1086/324356

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.

Authors:  Joao Tonolio Neto; Gabriela Tannus Branco de Araujo; Anna Gagliardi; Amanda Pinho; Laure Durand; Marcelo Fonseca
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey.

Authors:  Levent Akin; Mehmet Kaya; Serdar Altinel; Laure Durand
Journal:  Hum Vaccin       Date:  2011-04-01

Review 3.  Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers.

Authors:  Shawn A N Gilchrist; Angeline Nanni; Orin Levine
Journal:  Am J Public Health       Date:  2012-02-16       Impact factor: 9.308

4.  Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries.

Authors:  S M A A Evers; A J H A Ament; G L Colombo; H B Konradsen; R R Reinert; D Sauerland; K Wittrup-Jensen; C Loiseau; D S Fedson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

Review 5.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

Review 6.  Pneumococcal vaccination of older adults: conjugate or polysaccharide?

Authors:  David S Fedson; Martin J Guppy
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

7.  Policymaking based on CERs: changes in costs are not the same as changes in benefits.

Authors:  Andre Jha Ament; Silvia Mma Evers
Journal:  Cost Eff Resour Alloc       Date:  2005-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.